67. Polycystic kidney disease Clinical trials / Disease details


Clinical trials : 221 Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05478083
(ClinicalTrials.gov)
June 1, 20229/5/2022A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver DiseaseA GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver DiseasePolycystic Liver Disease;Autosomal Dominant Polycystic KidneyDrug: LeuprorelinUniversity Medical Center GroningenRadboud University Medical CenterRecruiting18 Years45 YearsFemale36Phase 2Netherlands
2EUCTR2020-005949-16-NL
(EUCTR)
25/10/202121/10/2021A study into the efficacy and toleratability of leuprorelin by patients suffering from severe polycystic liver diseaseA GnRH Agonist IN pre-menopausal women STudy to treat severe Polycystic Liver Disease - AGAINST-PLD Severe polycystic liver disease in female patients
MedDRA version: 20.1;Level: PT;Classification code 10048834;Term: Polycystic liver disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Level: LLT;Classification code 10036045;Term: Polycystic kidney;Classification code 10036046;Term: Polycystic kidney, autosomal dominant;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 23.0;Classification code 10083939;Term: Autosomal dominant polycystic liver disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Trade Name: Lucrin
Product Name: Lucrin
University Medical Center GroningenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: no
36Phase 2Netherlands